Uldis KALNINS*

(27.12.1946 - 23.12.2004.)

• Clinical Cardiology
• Genetic Markers of Coronary Heart Disease
• Acute Coronary Syndromes
• Prevention, Registries and Outcome Research
• Exercise testing and Rehabilitation
• Medical Education

• M.D., Riga Medical Institute, 1965-1971
• Internship, Internal Medicine, 1971-1973
• Residency, Cardiology, Riga Medical Institute, 1974-1976
• Dr. med. (Ph.D.): Cardiology, Kaunas Medical Institute, Lithuania, 1981
• Certificate: Electrophysiology and Pacing. Kaunas Medical Institute, Lithuania, 1985
• Certificates: Foundations of Public Health (Part I and Part II). The Nordic School of Public Health, Göteborg, Sweden, 1994; 1995
• Certificate: Epidemiological Methods in Public Health. London School of Hygiene & Tropical Medicine, Prague, 1994
• Certificate: Course on Interventional Cardiology. Heart Center & Red Cross Hospital, Frankfurt, German, 1995; 1996

• Research Fellow (Cardiology), Riga Medical Institute, 1976-1978
• Research Associate (Cardiology), Latvian Institute of Cardiology, 1979-1991
• Head, Lab. for Coronary Heart Disease Research, Latvian Institute of Cardiology, 1991-2004
• Chief, Latvian Centre of Cardiology, P. Stradins Clinical University Hospital, 1993-2004
• Invited speaker, Meetings and Seminars organized by Latvian Society of Cardiology, Latvian Institute of Cardiology, Medical Academy of Latvia, 1982- 2004
• Associate Professor (Cardiology), University of Latvia, Faculty of Medicine, 2001-2004

• Corresponding Member, Latvian Academy of Sciences, 2004
• The Three Stars Order (Republic of Latvia),  2003

• Member, Latvian Society of Cardiology, 1976-2004
• Member, Latvian Medical Association, 1989-2004
• Member, Association of Scientists in Latvia, 1990-2004
• Member, Working Group on Exercise Physiology, Pathophysiology and Electrocardiography, ESC, 1992-present
• Member, International Society and Federation of Cardiology, 1993-2004
• Member, Working Group on Coronary Circulation, ESC, 1994-2004
• Chairman, the Council on Prevention of CHD in Latvia, 1995
• Fellow of the European Society of Cardiology, 1995
• Member, New York Academy of Sciences, 1997
• Vice-President, Latvian Medical Association, 1999-2002
• President, Latvian Society of Cardiology, 2000 - 2004
• Fellow of the American Collage of Cardiology, 2004

• The 3^rd Baltic Atherosclerosis Congress and The 1^st International Congress of the Latvian Society of Cardiology. Riga, Latvia, May 20-22, 2004.
• International educational course organized by the European Society of Cardiology “Antithrombotic, fibrinolytic and interventional treatment of unstable angina and myocardial infarction”. Riga, Latvia, October 17-19, 2002.
• International conference “10 years of coronary angioplasty in Latvia”. Riga, Latvia, June 21-22, 2000.
• International educational course organized by the European Society of Cardiology “Update on cardiology: coronary heart disease and heart failure”. Riga, Latvia, Nov. 30 – Dec. 1, 2000.

• J. Volkolakovs, N. Andrejevs, U. Kalnins, O. Putnins, A. Ozols, G. Pulmane. Determination of indications for coronary angiography on the basis of results of bicycle and respiration ergometry.  - Cardiology (Moscow), 1983; 23(6):45 - 50 (in Russian, summary in English)
• U. Kalnins, I. Skarda, D. Liepina, A. Vitols. The development of coronary insufficiency during prolonged treatment of essential hypertension.  - Cor et Vasa, 1990; 32(I):64-71
• U.Kalnins, A. Erglis, S. Borovski. Exercise and pacing tests for diagnosis of single coronary artery disease.  - J. of Electrocardiology, 1993,v.26, N2,p. 171-172
• D.Matisone, J.Skards, I.Kukulis, A.Vitols, V.Dzerve, D.Liepina, D.Klincare, D.Basko, U.Kalnins, J.Jirgensons, M.Bertholds. Two different hemodynamic response patterns ensuring the hypotensive effect of sustained - release verapamil (Flamon 240 SP) in essential hypertensives.  - Acta Medica Baltica, 1996, p. 115-128
• K.Heidemanis, I.Dabina, U.Kalnins, A.Erglis, I.Dinne. Inhibition of sterol synthesis: yet another mechanism proposed for protective effect of high density lipoprotein.  - Can. J. Cardiol. 1997; v. 13. (suppl. B.), p. 98 B (0312)
• I.Skarda, V.Dzerve, D.Klincare, A.Vitols, U.Kalnins, I.Dinne I.Kalvins. Influence of longterm mildronate treatment on quality of life and hemodynamic parametrs of congestive heart failure patients.  - J. Heart Failure, 1997; v. 4(1): 53
• K.Heidemanis, U.Kalnins, I.Dabina, I.Dinne, A.Erglis. A new aspect of antiatherogenic action of plasma high-density lipoproteins: inhibition of cholesterol biogenesis.  - Baltic Atheroscl. J., 1999; 1: 53-55
• Tretjakovs P., Kalnins U., Dabina I., Dinne I., Erglis A., Jurka A. Interaction between arachidonic acid and platelet phospholipids, and HDL-cholesterol metobolism in patients with coronary heart disease.  - Acta Medica Austriaca, 1999; 26(S49): 6-7
• P.Tretjakovs, U.Kalnins, I.Dabina, I.Dinne, A.Erglis, I.Kumsars, A.Jurka. Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia.  - Med Sci Monit, 2000; 6 (3): 507-511
• P.Tretjakovs, U.Kalnins, I.Dabina, I.Dinne, A.Erglis, A.Jurka. Nitric oxide and cutaneous vasomor response in coronary artery disease patients.  - Atheroslerosis, 2000; 15 (1): 11-12
• U.Kalnins, P.Tretjakovs, A.Erglis, I.Dinne, I.Dabina, A.Jurka. Changes in nitric oxide production and arachidonic acid metabolism in platelet membrane in coronary heart disease patients after coronary angioplasty.  - Heart, 2000; 83 (Sppl. II): A 13,51
• R.S. Karpov, O.A. Koshelskaya, A.V. Vrublevsky, A.A. Sokolov, A.T. Teplyakov, I. Skarda, V.Dzerve, D.Klintsare, A.Vitols, U.Kalnins, I.Kalvinsh, L.Matveya, D. Urbane. Clinical Efficacy and Safety of Mildronate in Patients With Ischemic Heart Disease and Chronic Heart Failure.  - Kardiologiya, 2000, N6: 69-74 (In Russian, summary in English)
• Tretjakovs P., Kalnins U., Dabina I., Dinne I., Erglis A., Kumsars I., Jurka A. Relationship between nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary artery disease patients.  - Latvijas Universitates Zinatnisko rakstu krajums, Medicina, 2001; 631(4): 134-143
• P.Tretjakovs, U.Kalnins, I.Dabina, I.Dinne, A.Erglis, G.Latkovskis, A.Jurka. Effect of HDL-cholesterol on nitric oxide production and turnover of phospholipids in platelet membranes in CAD patients. - Baltic Atheroscl. J, 2001, 2: 21-24
• P.Tretjakovs, U.Kalnins, I.Dabina, I.Dinne, A.Erglis, G.Latkovskis, A.Jurka. Nitric oxide production and arahidonic acid metabolism platelet membranes of diabetic and coronary artery disease patients.  - 14^th International Symposium on Drugs Affecting Lipid Metabolism, New York, 9-12 Sept., 2001., p.100
• V.Rudzite, A.Silava, U.Kalnins, A.Erglis, M.Jaeger, K.Trusinskis, D.Fuchs. Association between increased serum neopterin and homocysteine concentrations as well as pyridoxal deficiency in patients with coronary heart disease. -  Pteridines, 2001;12:130-134
• U.Kalnins, A.Erglis, I.Dinne, I.Kumsars, S.Jegere. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. - Med. Sci. Monit., 2002; 8 (2): 16-20
• P.Tretjakovs, U.Kalnins, I.Dabina, A.Erglis, I.Dinne, A.Jurka, G.Latkovskis, A.Zvaigzne, V.Pirags. Arachidonic acid methabolism and nitric oxide production in platelet membranes of coronary artery disease patients with and without diabetes. - Proc. Latvian Acad. Sci, Section B, 2002; 56, 3:109-113
• V.Rudzite, A.Jurika, U.Kalnins, A.Erglis, K.Trusinskis, S.Jegere, B.Frick, D.Fuchs. Comparing the sensitivity of pyridoxal-5-phospate, homocysteine and neoptrin in coronary heart disease.  - Pteridines, 2002;13(3):100-103
• V.Rudzite, E.Jurika, U.Kalnins, A.Erglis, K.Trusinskis, S.Jegere. Changes in lipid metabolism in patients with coronary heart disease. - Proc. Latvian Acad.Sci, Section B, 2002;56(3)
• P.Tretjakovs, U. Kalnins, I. Dabina, A. Erglis, I. Dinne, A. Jurka, G. Latkovskis, A.Zvaigzne, V. Pirags. Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. -   Med. Principles Pract., 2003; 12(1):10-16
• M.Haude, T.F.M.Konorza, U.Kalnins, A.Erglis, K.Saunamäki, H.D.Glogar, E.Grube, R.Gil, A.Serra, H.G.Richard, P.Sick, R.Erbel for the heparin - COAted STents in small coronary arteries (COAST) trial investigators. Heparin-coated stent placement for treatment of stenosis in small coronary arteries of symptomatic patients. -   Circulation 2003; 107:1265-1270
• G.Latkovskis, U.Kalnins, G.Sika, M.Vikmane, M.Vitola. Evaluation of secondary prevention measures in patients with coronary heart disease in Latvia.  - Seminars in Cardiology, 2003; 9(1):28-37
• Frick B., Rudzite V., Schröcksnadel K., Kalnins U., Erglis A., Trusinskis K., Fuchs D. Homocysteine, B vitamins and immune activation in coronary heart disease. -   Pteridines, 2003; 14: 82–87
• A.Erglis, U.Kalnins, A.Saltups, I.Kumsars, I.Dinne, D.Sondore, I.Narbute, S.Jegere, U.Jaspers. The influece of balloon material on stent geometry and acute gain during intravascular ultrasound guided stenting. - Seminars in Cardiology, 2003; 9(2): 38-45
• Gil-Extermera B., Ma P.T., Yulde J., Kalnins U., Harkin N., Williams L. The adjunctive effect of telemisartan in patients with hypertension uncontrolled on current antihypertensive therapy.  - Int.J.Clin.Pract. 2003;57(10):861-866
• Rudzite V., Jurika E., Fuchs D., Kalnins U., Erglis A., Trusinskis K. Serum concentration of C-reactive protein, neopterin and phospholipids in patients with different grade of coronary heart disease. -  Pteridines, 2003, 14:133-137
• B.Wirleitner, V.Rudzite, G.Neurauter, C.Murr, U.Kalnins, A.Erglis, K.Trusinskis, D.Fuchs. Immune activation and degradation of tryptophan in coronary heart disease. - Eur. J. Clin. Invest., 2003;33 (1): 550–554
• Rudzite V., Jurika E., Fuchs D., Kalnins U., Erglis A., Trusinskis K. The significance of secondary risk factors in the course of coronary artery disease (CAD).  - 23^rd International Winter-Workshop on Clinical, Chemical and Biochemical Aspects of Pteridines. St.Christoph/Arlberg, Austria,February 28–March 6^th 2004. Pteridines, 2004; 15
• U.Kalnins, A.Erglis, A.Rudzitis, M.Schneider, F.Kohler. Interventional cardiology in Latvia 1993-2003. -  Dtsch.Med.Wochenschr. 2004;129 (Suppl.1): S29-S32.
• Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. -  European Journal of Immunogenetics, 2004; 31:207-213
• U.Kalnins Is statin therapy indicated for patients with acute coronary syndrome?   - Seminars in Cardiology, 2004; 10(1): 7-10
• P. Tretjakovs, U. Kalnins, A. Jurka, S. Steina, R. Ritenberga, M. Marga, A. Stifts, V. Pirags. Naftidrofuryl, a serotonin 5-HT2 receptor inhibitor, improves vasomotor responses in diabetics with atherosclerosis. - Seminars in Cardiology, 2004; 10(2):101-108
• Sick P.B., Gelbrich G., Kalnins U., Erglis A., et al. Comparison of early and late results of Carbofilm-coated stents versus a pure high-grade stainless steel stent (the Carbostent trial).  - Am. J. Cardiol. 2004; 93(11):1351-1356

• Clinical efficacy and cost–effectiveness of coronary stenting with special stents in stable and unstable angina taking into account genetic and inflammatory risk factors. Latvian Council of Science (2001-2004).
• Angiogenic factors of platelets and leucocytes in patients with coronary atherosclerosis and their role in the course of invasive treatment. Latvian Council of Science (2001-2004) (in collab. with P.Tretjakovs).
• Study and evaluation of secondary risk factors, conditions in the development and progression of coronary heart disease. Latvian Council of Science (2001 - 2004) (in collab. with Prof. V.Rudzite).
• Genetic markers of coronary heart disease and its different forms. Latvian Council of Science (2001-2004). In collab. with Prof. E.Grens and Prof. A.Krumina project “Genomic studies in the Latvian population in relation to human pathology”.
• Balloon angioplasty vs heparin coated and non-coated coronary stents (COAST). In collab.with Prof. Dr. R.Erbel, University Hospital Essen, Dept. of Cardiology, Hufellandstr. 55, D-45147 Essen, Germany (1999-2001).
• Prospective randomized comparison of the restenotic process measured by the increase of the degree of percent stenosis using a carbofilm coated stent (Sorin Biomedica) and a pure high-grade stainless steel stent (S 670 or 540, Medtronic AVE) a multicentre study (The CARBO film-STENT-Study). (2000-2003) In collab. with Prof. Dr. Gerhard Schuler, Dr. Peter Sick, University of Leipzig, Heart Center, Russenstrape 19, D-04289 Leipzig, Germany.
• European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). (1998-2003). Member of the Steering Committee for the EUROPA study (sponsored by Servier International).
• Occluded Artery Trial (OAT). Collab. with the National Institute of Health, USA (from 2002).
• Research of new cardiovascular risk factors (insulin resistance and endothelial dysfunction) in patients with coronary atherosclerosis. Applied to the Latvian Council of Science (in collaboration with A.Jansone).

Last update 03.01.2005